Research Library · Peptide Science & Clinical Evidence

📚 Research Library

Peptide Science & Clinical Evidence · A Curated Repository of Literature, Trials, and Practical Guides
TL;DR · The Research Library is a comprehensive, evidence‑based repository of peptide‑related scientific literature, clinical trial data, regulatory documents, and practical guides. It is organized by topic—from GLP‑1 agonists and senolytics to emerging peptides and regulatory compliance—to support clinicians, researchers, and informed patients. The library is continuously updated with peer‑reviewed publications, FDA guidance, and real‑world evidence. All content is for educational purposes and should not replace professional medical advice.

📑 Contents

About the Library Collections GLP‑1 & Metabolic Peptides Senolytics & Longevity Performance & Recovery Emerging Peptides Regulatory & Safety Tools & Resources FAQs Disclosure & Disclaimer

About the Research Library

The Research Library is a centralized, open‑access repository of peptide‑related scientific literature, clinical trial data, regulatory documents, and practical guides. It is designed to serve clinicians, researchers, students, and informed patients who seek evidence‑based information on peptide therapeutics.

1,200+
Peer‑reviewed papers
85
Clinical trial summaries
32
FDA/EMA guidance documents
25
Practical clinical guides
6
Topic collections

All content is curated from reputable, peer‑reviewed journals, regulatory agencies (FDA, EMA, TGA), and clinical trial registries (ClinicalTrials.gov). The library is updated quarterly to reflect the latest evidence.

📖 “Evidence is the foundation of safe and effective peptide therapy. This library is our commitment to that principle.”

Collections

The library is organized into six primary collections, each covering a key therapeutic area.

🩸
GLP‑1 & Metabolic Peptides
Semaglutide, tirzepatide, retatrutide, amylin analogs, and dual/triple agonists for obesity, T2DM, and MASH.
230+ papers
🧬
Senolytics & Longevity
Dasatinib + quercetin, fisetin, BCL‑2 inhibitors, and emerging senotherapeutic peptides.
140+ papers
🏃
Performance & Recovery
BPC‑157, TB‑500, CJC‑1295, ipamorelin, GHK‑Cu, and recovery‑focused peptides.
180+ papers
🔬
Emerging Peptides
Ultralong‑acting triple agonists, amyloid‑production inhibitors, marine‑derived regenerative peptides, and peptide‑based PROTACs.
110+ papers
⚖️
Regulatory & Safety
FDA 503A Category 2, compounding regulations, WADA prohibited list, and adverse event surveillance.
90+ documents
🛠️
Tools & Resources
Dosing calculators, CGM interpretation guides, clinical decision aids, and patient handouts.
25+ tools

GLP‑1 & Metabolic Peptides

This collection covers the full spectrum of incretin‑based therapies, from first‑generation GLP‑1 agonists to next‑generation multi‑agonists.

📚 Key Publications

  • Semaglutide 2.4 mg (STEP trials): Wilding JPH, et al. NEJM 2021;384:989‑1002. — 68‑week weight loss of 14.9% .
  • Tirzepatide (SURMOUNT‑1): Jastreboff AM, et al. NEJM 2022;387:205‑216. — 15 mg achieved 20.9% weight loss .
  • Retatrutide (Phase 2): Jastreboff AM, et al. NEJM 2023;389:514‑526. — 12 mg achieved 24.2% weight loss .
  • ASC37 (Preclinical): Ascletis Pharma, 2026. — Once‑monthly triple agonist, 5‑4× more potent than retatrutide .
  • MASH indications: Multiple trials showing GLP‑1 benefits in MASH, with ongoing Phase 3 .
📊 “The metabolic peptide revolution is transforming obesity care—and the evidence base is growing rapidly.”

Senolytics & Longevity

This collection focuses on agents that target cellular senescence—a key driver of aging and age‑related disease.

📚 Key Publications

  • Senolytic combination (D+Q): Hickson LJ, et al. EBioMedicine 2019;47:446‑456. — First human trial showing senescent cell clearance .
  • Fisetin (FAST‑K): Yousefzadeh MJ, et al. EBioMedicine 2021;68:103413. — Reduced senescent cell burden in human trial .
  • Navitoclax (ABT‑263): Chang J, et al. Nat Med 2016;22:78‑83. — Senolysis in mouse models, but thrombocytopenia limits use .
  • Next‑gen senolytics: Immune‑based approaches (CAR‑T targeting uPAR) and tissue‑specific PROTACs .
  • Clinical trials: Ongoing studies in Alzheimer’s, pulmonary fibrosis, diabetic kidney disease, and osteoarthritis .
🧬 “Senolytics are moving from bench to bedside—but the evidence base is still maturing.”

Performance & Recovery Peptides

This collection covers peptides popular in sports medicine, biohacking, and recovery contexts, with a critical emphasis on the evidence gap.

📚 Key Publications

  • BPC‑157 & TB‑500 Review: Hussain N, et al. Am J Sports Med 2026. — Preclinical promise but “largely unvalidated in human trials” .
  • CJC‑1295 Phase 1: Teichman SL, et al. J Clin Endocrinol Metab 2006;91:1370‑1376. — GH elevation up to 10 days, but no efficacy data .
  • PeptiStrong™ Human Trial: Designs for Health, 2024. — 14‑day study in 30 healthy men showing improved recovery .
  • WADA Prohibited List 2026: Most performance peptides banned in‑ and out‑of‑competition .
⚠️ “The performance peptide literature is dominated by preclinical data and anecdote. Rigorous human trials are urgently needed.”

Emerging Peptides

This collection captures the cutting edge of peptide science—beyond GLP‑1, into new modalities and disease areas.

📚 Key Publications

  • ASC37 (Obesity, once‑monthly): Ascletis Pharma, 2026. — Triple agonist with ultra‑long PK profile .
  • 8M2D (Alzheimer’s, amyloid production inhibitor): Cenna Biosciences, 2026. — First‑in‑class peptide in Phase 1 .
  • FPP (Marine regenerative peptide): Zhang X, et al. Front Nutr 2025;12:1547890. — From sea squirt peptidome, shows tissue repair in zebrafish .
  • Peptide‑based PROTACs: RSC Chem Biol 2026. — Stabilized helical peptides as recognition modules for targeted protein degradation .
  • Programmable peptide engineering: Review on secondary structure control, AI‑enabled design, and chemoselective ligation .
🔬 “Emerging peptides are redefining what’s possible—but they remain investigational. Evidence is the bridge to the clinic.”

Regulatory & Safety

This collection provides access to key regulatory documents, safety warnings, and compliance guides.

📄 Key Documents

  • FDA 503A Category 2 List (2026): AOD‑9604, CJC‑1295, and other peptides restricted from compounding .
  • FDA Drug Safety Communications: GLP‑1 agonist updates (pancreatitis, gallbladder disease, ileus).
  • WADA Prohibited List (2026): S2 – Peptide Hormones, Growth Factors, Related Substances and Mimetics .
  • EMA Peptide Guidance: Clinical development and quality considerations .
  • Theratechnologies Egrifta WR Approval: March 2025, new formulation for HIV‑associated lipodystrophy .
  • ASC37 IND Submission: Q2 2026 expected .
⚖️ “Regulatory clarity is essential for safe peptide use. This collection tracks the evolving landscape.”

Tools & Resources

Practical tools to support clinical decision‑making and patient education.

  • Dosing Calculators: GLP‑1 titration schedules, peptide reconstitution guides, and conversion tools.
  • CGM Interpretation Guide: Time‑in‑range, glucose variability, and response to peptide therapy.
  • Clinical Decision Aids: Patient selection checklists, contraindications, and monitoring protocols.
  • Patient Handouts: Peptide therapy overviews, side effect management, and lifestyle integration.
  • Literature Search Tools: Curated PubMed queries, clinical trial filters, and RSS feeds for new publications.
  • Visual Summaries: Mechanism‑of‑action graphics and clinical algorithm diagrams.
🛠️ “Knowledge is power—but tools make it actionable. This collection bridges evidence and practice.”

The Research Library is a living resource—continuously updated to reflect the latest evidence in peptide science. It is intended to support clinicians, researchers, and informed patients in making evidence‑based decisions. All content is curated from peer‑reviewed literature, regulatory sources, and clinical trial registries. As the field of peptide therapeutics continues to expand, this library will grow alongside it—providing a trusted foundation of knowledge in a rapidly evolving landscape.

❓ FAQs About the Research Library

How often is the library updated?
The library is updated quarterly, with major additions following FDA approvals, significant publications, or new clinical trial results.
Is the content peer‑reviewed?
Yes. All primary literature is sourced from reputable, peer‑reviewed journals. Regulatory documents and clinical trial data are sourced from official registries.
Can I suggest a paper or resource?
Yes. We welcome suggestions from researchers and clinicians. Submissions are reviewed by our editorial board for relevance and rigor.
Is the library free to access?
Yes. All content is freely accessible for educational and research purposes. Some resources may require a subscription via the original publisher.
Does the library provide clinical recommendations?
No. The library provides evidence summaries and data, but does not make clinical recommendations. All clinical decisions should be made by qualified healthcare providers.
How do I cite library content?
Cite the original source (journal article, FDA document, etc.) where available. For curated summaries, please cite the library as a secondary source.
Does the library cover all peptides?
No. The library focuses on peptides with significant clinical, preclinical, or regulatory interest—particularly those in obesity, metabolic health, longevity, and performance.

📌 Disclosure & Disclaimer

Disclosure: The Research Library is an educational and informational resource. The authors and curators have no financial ties to any pharmaceutical or biotechnology companies mentioned. References reflect current scientific literature and regulatory documents, not endorsements.

Disclaimer: This content does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider for personalized medical decisions. The library is not a substitute for professional judgment.

📚 PS — Knowledge Is the Foundation of Safe Practice
Peptide therapeutics are advancing rapidly—but so must our understanding of their evidence base, safety profile, and regulatory status. The Research Library exists to support that mission: to provide clinicians and patients with the tools and information they need to make informed, evidence‑based decisions.

Stay curious. Stay informed. And always follow the evidence.

Science advances. So should we.

✧ Written in service of evidence‑based medicine and patient safety ✧